The partnership combines the companies’ resources to focus on Axiomer, a technology that can edit single nucleotides in RNA in a specific and highly targeted manner.
Scientists from different agencies and research facilities have turned to laboratory manufactured human mini-brains to study the onset and progression of Parkinson’s disease.
The collaboration between Spark and NeuExcell increased the hope for Huntington’s disease cure in near future. This is going to be a great relief for all the patients.
Swedish Orphan Biovitrum AB (Sobi) has received an $8 billion (68 billion kronor) cash buyout offer from Advent International, valuing its shares at SEK 235 each.
The Sacklers did not admit to any wrongdoing and have never been charged directly for the issue. Still, Purdue Pharma has pleaded guilty twice in its erroneous marketing efforts for OxyContin.
Takeda said that Phase III PANTHER, which studied the effectiveness of pevonedistat for different types of leukemia, did not produce significant results in terms of event-free survival.
ZN-c3 is a WEE1 inhibitor that could be used as monotherapy for uterine serous carcinoma and solid tumors, as well as combination therapy for ovarian cancer, alongside chemotherapy.
Mesoblast shares dropped on the last day of August 2021 after it was told that its candidate COVID-19 treatment needs to undergo another trial to be green-lit for emergency approval by the FDA.
A new study on COVID-19 behavior has found that patients affected by the virus might have died due to a buildup of coronavirus directly in the lungs and not because of a secondary infection.
